Rodriguez Susan
Known title: Chief Commercial OfficerCIK: 0001812511
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Transaction History
| HRTX | ▲ Buy | Grant | 17,950 | $0 | 1/30/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 6,703 | $52K | 5/21/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 6,928 | $61K | 2/20/2024 | View on chart |
| HRTX | ▲ Buy | Grant | 13,948 | $0 | 1/19/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 112,750 | $0 | 1/16/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,714 | $21K | 11/20/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,733 | $17K | 8/21/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,711 | $17K | 5/23/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,586 | $17K | 2/21/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 78,000 | $0 | 1/5/2023 | View on chart |
| HRTX | ▲ Buy | Grant | 38,580 | $0 | 12/16/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 131 | $254 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 22 | $43 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,303 | $6K | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,356 | $3K | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 64 | $63 | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 43,010 | $28K | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 910 | $578 | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,425 | $2K | 5/20/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,400 | $2K | 2/22/2022 | View on chart |
| ARDX | ▲ Buy | Grant | 141,000 | $0 | 1/6/2022 | View on chart |
| HRTX | ▲ Buy | Grant | 10,452 | $0 | 12/22/2021 | View on chart |
| ARDX | ▼ Sell | Open Market | 643 | $638 | 11/22/2021 | View on chart |
| ARDX | ▲ Buy | Grant | 150,000 | $0 | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Heron Therapeutics Signs U.S. License Deal
Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.
Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.